Replies to post #15356 on GTC Biotherapeutics (fka GTCB)

[Lewis R Goudy]

Least squares fit of fully-diluted tally to exponential model?

[DragonBits]

Dew, interesting but what did they do wrong? How could they have avoided this?

It is easy to say sign better deals, but we have to assume they signed the best deals they could find. Even idiots will do that much.

I can see they borrored money to buyback stock from Genzyme, that loan is still on their books. To me that was a negative indication of management. I ignored that in the past and lost money on GTCB, but I was being a little to greedy and on vacation, and didn't sell at the pop to above 2.00. I knew this wasn't ready for prime time.

The issue is, seeing all these negatives, why invest here at all? One can watch the science without having to be a part of funding it with little chance of gain.

The stock may soar at some point, but I wonder if anyone that has an average price of 0.70+ will ever get their money back.

And if GTC is so valuable, it seems to me LFB can slow roll DIC, boost the upfront costs to GTC, and eventually own most of the company.

I suppose that is why you want to vote no on the loan, but far easier to have sold out when the stock was above 1.00 and you could see that this wasn't going as planned.

[stockdak]

What an eye opener. IMO DDs post shows that the current management has no credibility and gives no thought of going to the well with ever more ruinous terms. I had been giving them the benefit of the doubt. This last announcement makes little sense for shareholders no matter how much "stay the course" rhetoric is espoused here. I have been fooled by this "in some style" hyperbole and promises of partnerships that do not come in or if they do with not enough upfront cash to sustain the company. As I see it with this arrangement even if they do get approval in Feb, get milestone payments, and sign a partnership with a $10 mil. upfront they would still need to do a further dilution to sustain the company going forward. This management has completely failed to get enough cash when cash was available to sustain the company to cash flow positive. I voted my shares against the proposal and am selling down my shares with the largest losses I have ever taken in 20 years of trading. Why? Because the evidence in front of me says Cox and company have a long history of regulatory blunders and badly timed financing. It is likely that the proposals will pass and IMO the terms are so egregious that little value will remain for current shareholders even with Atryn approval in Feb.

[cash2go]

Why no ATryn sales in Europe?

Apporved in 2006

FRAMINGHAM, MA - August 2, 2006 -- GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) reported today that the European Commission has granted market authorization to ATryn®, GTC's recombinant form of human antithrombin, for the prophylaxis of venous thromboembolism in surgery of patients with congenital antithrombin deficiency

http://www.gtc-bio.com/pressreleases/pr080206.html

Looks like a lot of selling on the news as ATryn will not be a big seller? The dilution coming from recent financing activities will also be weighing shares down for a while. Great Headlines should bring in the traders Monday. Long term is what I'm interested in.
Any other companies working in genetically altered animals producing human protiens that look intersting to anyone.

Zero knowledge base in this one, myself. Hope to see the long term investors weigh in on the potential here and what would be a good entry point.